Avanafil (stendra) Powder (330784-47-9)

Avanafil (stendra) Powder (330784-47-9)

Product name:Avanafil
Assay:99% min.
CAS:330784-47-9
Molecular Formula:C23H26ClN7O3
Molecular Weight:483.95
Melting point:150-152°C
Density:1.372
MF:Good Quality 99% Avanafil CAS: 330784-47-9
Storage condition:Refrigerator
Character:White to Off-White Cyrstalline Solid.
Usage:Used for the treatment of erectile dysfunction. A phosphodiesterase 5 inhibitor.
Categories:Active Pharmaceutical Ingredients; Cnbio; Erectile Dysfunction; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; API’s.

Avanafil Description:

Avanafil is an oral drug that is used for treating impotence (the inability to attain or maintain a penile erection), also known as erectile dysfunction (ED).

It is in a class of drugs called phosphodiesterase inhibitors that also includes tadalafil (Cialis), sildenafil (Viagra) and vardenafil (Levitra). Erection of the penis is caused by the filling of the penis with blood. Filling occurs because the blood vessels that bring blood to the penis increase in size and deliver more blood to the penis, and, at the same time, the blood vessels that take blood away from the penis decrease in size and remove less blood from the penis.

Sexual stimulation that leads to an erection causes the production and release of nitric oxide in the penis.

Avanafil Application:

The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30-45 minutes.About two-thirds of the participants were able to engage in sexual activity within 15 minutes.

Avanafil Usage:

It is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding to oral dosage forms of patients.

Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, in vitro experiments showed that the selectivity of phosphodiesterase 5 stronger than . The compound dear compliance weak against other phosphodiesterase, and effect of adenosine receptor decreased, suggesting that the cardiovascular effects of avanafil should be weaker than .

Pre clinical study showed that avanafil and organic nitrate drugs taken in combination to reduce its on blood pressure was significantly weaker than and nitrate drugs with clothes. Moreover, avanafil inhibition of phosphodiesterase 6 is very weak, the relevant visual disturbance suppression may the enzyme phosphodiesterase 5 inhibitor induced and other.

Avanafil COA:

Avanafil ​Function:

Erects within 5 minutes, erection lasts Min. 72 hours.Focus on sexuality enhancements improving energy level.Used in the treatment of penile erectile dysfunction (ED).

Avanafil ​Dosing:

Usual Adult Dose for Erectile Dysfunction:

Initial dose: 100 mg orally as needed approximately 30 minutes before sexual activity.
Maintenance dose: 50 to 200 mg orally as needed 30 minutes before sexual activity.
Maximum dose: 200 mg orally once a day.